OrderlyMeds is medication-forward and does not dress it up. Low-cost plans at $149 a month with 503A compounding, and no claim to be managing anything beyond the prescription. In a market where several providers imply more care than they deliver, the plainness is worth acknowledging.
Measured against this Charter it scores low, and that is a statement about scope rather than competence. No whole-person or hormonal context is part of the model, which produces zeroes on the first three rows.
Here is how OrderlyMeds reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
The plan covers medication with 503A compounding at a price near the bottom of this page. Dose fit, human help and cost each sit at partial, describing a service that is transparent about a deliberately narrow offering. For someone whose clinical care is genuinely handled elsewhere, that narrowness is the product rather than a shortfall.
There is no clinician relationship built around your history, no route for a pain pattern to inform anything, and no plan for the phase after weight loss. If your endometriosis is well managed by a specialist and you need supply, none of that matters. If this was going to be the place where things finally got joined up, it is not.
Put these to OrderlyMeds in writing, and keep the reply.
OrderlyMeds rates low on this Charter and high on honesty about its own scope. As affordable, clearly-priced medication access alongside specialist care elsewhere, it does the job it describes.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.